Latest / Stock Movers / Paypal Sinks on Abandoned Deal, Affirm Rallies, BioNTech Slumps
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio.
- 0:06Speaker 2: News.
- 0:08Speaker 1: The Stock Movers Report. Your roundup of companies making moves
- 0:12Speaker 1: in the stock market. Harnessing the power of Bloomberg data.
- 0:17Speaker 1: Let's take a look at some stocks on the move today.
- 0:19Speaker 1: I'm Tim Stenevek with Lisa Mateo. We're joined by Bloomberg
- 0:22Speaker 1: News Markets Live strategist Tatiana Daria. Hey, Tatiana.
- 0:25Speaker 2: How are you doing?
- 0:26Speaker 1: Good.
- 0:26Speaker 3: Good to be here.
- 0:27Speaker 2: So what do you got for us?
- 0:29Speaker 3: I'll start with PayPal. The big mover off at the
- 0:32Speaker 3: day down 12% after....
- 0:34Speaker 4: Buyout firm Advent and payment processor Stripe decided to abandon
- 0:38Speaker 4: its pursuit of the firm. Obviously, the big story today,
- 0:41Speaker 4: that deal would have been one of the largest buyout
- 0:44Speaker 4: deals in history with an offer of more than $ 50 billion.
- 0:49Speaker 4: That's how it would have translated for its overall valuation.
- 0:54Speaker 4: And PayPal said that was insufficient. It's worth noting that
- 0:58Speaker 4: it has been trading at a market cap of about
- 1:00Speaker 4: $ 40 billion just before Bloomberg broke that story back in
- 1:03Speaker 4: February that Stripe had an interest in the story. And
- 1:06Speaker 4: obviously that bid has been a source of support for
- 1:09Speaker 4: the stock.
- 1:10Speaker 3: Well, obviously now it's a source of its weakness.
- 1:13Speaker 4: Nonetheless, analysts here still see PayPal as a potential attractive target.
- 1:19Speaker 4: as valuation has cheapened over the years a lot.
- 1:21Speaker 3: That would have been a big deal.
- 1:23Speaker 2: A firm.
- 1:24Speaker 3: We just had the CEO we were just speaking with.
- 1:26Speaker 2: Who's a member of the PayPal mafia. He was one
- 1:28Speaker 2: of the early PayPal executives. So there's always a PayPal connection.
- 1:32Speaker 4: Great, that's the connection there. Well, a firm share up
- 1:36Speaker 4: about 4% was up about 17% earlier, the most in
- 1:40Speaker 4: the year. This is all after an upbeat revenue forecast
- 1:44Speaker 4: for the first quarter. The FinCAP company is doing pretty well.
- 1:48Speaker 4: It has guided for about $ 1. 2 billion versus estimates of
- 1:51Speaker 4: $ 1. 17 billion. Yes, we care what follows the decimal point here.
- 1:56Speaker 4: But it has also posted huge earnings growth. Four-quarter EPS,
- 2:02Speaker 4: $ 4. 62 versus $ 0.
- 2:04Speaker 3: 20 year-over-year. I had to double-check this. This is huge growth.
- 2:06Speaker 3: I can't even do the math here of how big
- 2:09Speaker 3: the growth is.
- 2:10Speaker 4: Revenue over a billion, also higher by 30% year-over-year. And
- 2:14Speaker 4: you just have to ask yourself, what does this all
- 2:17Speaker 4: mean by the consumer? Obviously, the buy now, pay later.
- 2:20Speaker 4: platforms seem to be very, very popular. But as a
- 2:23Speaker 4: macro strategist, I always try to dissect what is the
- 2:26Speaker 4: macro message here. The CEO would probably not like me
- 2:30Speaker 4: looking into that as a signal about the health of
- 2:32Speaker 4: the consumer.
- 2:33Speaker 3: But nonetheless, you have to ask yourself that question.
- 2:35Speaker 2: Yeah, he did just tell us that the Affirm customer
- 2:39Speaker 2: is healthy, his customer. Because we talked to him a
- 2:42Speaker 2: lot and he He's always very specific about the customer
- 2:45Speaker 2: that he sees.
- 2:45Speaker 3: I mean, it makes sense.
- 2:47Speaker 2: And yeah, he says it's healthy, though. He says the
- 2:49Speaker 2: company is slightly more restrictive than it was a year ago.
- 2:53Speaker 4: Okay.
- 2:54Speaker 2: That's a firm. What else you got for us?
- 2:56Speaker 4: In BioNTech ADRs, that's the German BioNTech firm known for
- 3:01Speaker 4: its COVID-19.
- 3:02Speaker 3: Shot that developed with Pfizer.
- 3:05Speaker 4: Down about 8% was down as much as 18% earlier.
- 3:09Speaker 4: That's after it terminated in an advanced trial with Roche
- 3:14Speaker 4: that it was developing for a personalized mRNA cancer test.
- 3:17Speaker 3: Vaccine.
- 3:18Speaker 4: And this is a real setback, especially after hopes have
- 3:22Speaker 4: risen after those blowout results from Merck with Moderna on
- 3:26Speaker 4: the melanoma, and that they found really great results and
- 3:31Speaker 4: it raised hopes about the mRNA's second act here after COVID. Well,
- 3:36Speaker 4: now this is raising real questions about can this technology
- 3:40Speaker 4: work in other tumors, particularly solid tumors, which other companies,
- 3:43Speaker 4: including Moderna, are working on, and that's putting pressure on
- 3:46Speaker 4: that stock as well.
- 3:47Speaker 2: I mean, it would be remarkable to just see.
- 3:52Speaker 3: Real progress, but not linear, right?
- 3:54Speaker 2: Yeah, exactly.
- 3:54Speaker 4: It comes with setbacks as well. So we'll see what
- 3:59Speaker 4: mRNA has in.
- 4:00Speaker 1: Store for us.
- 4:01Speaker 2: All right. That's BeyondTech. The US ADRs remind us of
- 4:04Speaker 2: the ticker for that one?
- 4:06Speaker 3: It's BTNX.
- 4:07Speaker 2: BTNX for BeyondTech. That's Tatiana Dare. She's Markets Live Strategist
- 4:12Speaker 2: for Bloomberg News.
- 4:14Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 4:18Speaker 1: us throughout the day for the latest roundup of companies
- 4:21Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 4:25Speaker 1: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 4:30Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 4:33Speaker 1: Business app.